Discussion page for Arch Therapeutics (ARTH)This page is for discussion of Arch Therapeutics (ARTH).
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
I hope I can post an off topic Biotec I found this a few months ago and now it is beginning to get interesting. IIRC Biotec devices have shorter trial sizes. They spent 6 years with one of our National Labs developing an iron particle small enough to be coated with a biotec medium that attaches to a cancerous growth. $ASX:IBX – Imagion Biosystems Receives FDA Breakthrough Device Designation “Imagion Biosystems Limited (ASX: IBX) (the Company), a company dedicated to improving healthcare through the earlier detection of cancer, today announced that it has received notification from the Center for Devices… Read More »
Per ARTH 10Q on timing of CE mark: “Given the recent changes in the governing rules and the impact of Brexit, the review process has taken longer than anticipated. We now currently expect that the review process to be completed this fall.”
$ARTH – Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5™ Topical Hemostat
https://ir.archtherapeutics.com/press-releases/detail/527
AC5 keeps getting better “Studies highlight antimicrobial activity for AC5 technology platform; AC5™ Topical Hemostat1 under Review by Notified Body”. CE approval this Fall maybe not much longer.
ARTH long
$ARTH Long A nice press release – so a question for you all about their statement – “As a result, we currently expect the review process to be completed this fall, and we anticipate our next update to coincide with a definitive and material announcement.” So, what does TN mean by “our next update? ” Is that the monthly update they seem to make about the company or the next time they talk about the CE application? I really like this part “to coincide with a definitive and material announcement”. That seems to be really a positive statement that portends… Read More »
I’m not aware of any scheduled updates I’ve signed up for their newsletters, as I do with most all companies I’ve invested in, there are no scheduled updates that I’m aware of. I would think that they are working on one because this is the first I’ve heard of the antimicrobial and that needs to be elaborated on. I won’t guess as to which comes first CE approval or more antimicrobial data. Right now I’m just hoping it’s before November there are others more informed than I.
The definitive material announcement is going to be more dilution and more delays.
So are you going to sell the stock?
I don’t know, but I think anyone who’s been invested in this stock for years like I have should be concerned. How are you feeling about their financial position and their ability to raise money now in comparison to the post below from you a year ago, do you think this is still on track?: I worry a lot more about biotech companies that can’t raise money than those that can. This $4.5 million will carry ARTH into the December 2019 quarter, so we will get the results of the sensitization study, the 510(k) filing, the CE Mark filing, the… Read More »
Pretty much the same. The (unnecessary) sensitization study was good, the 510(k) was filed on time, the CE Mark was filed on time, the 510(k) was approved, the CE Mark approval is next, and the IND will be filed before he needs to raise money again.
Given the CE Mark delay, I don’t know if there’s time to sign a European distribution deal before he needs to raise money. He may squeeze by with warrant exercise proceeds if the CE Mark pops the stock enough.
In the meantime these Yahoo!’s collect $500,000 salaries. Send out a sentence or two every few months and ask for more money every few years.sheesh people. ???
Quite a good summary of Arch Therapeutics in Seeking Alpha
https://seekingalpha.com/article/4285493-examining-next-arch-therapeutics
yours, Finn
Anybody watch the Arch presentation yesterday. I missed it. Norci say anything new. Need something to get this stock to move. Thanks
Anyone hear ANYTHING at all? All I’ve heard is the sound of the SP dropping every time I check in online. 0.2675 today. I think that may be at or near the lowest it’s been since I’ve owned it (Summer 2015). Cleveland, any news?
Listen to the Wainwright presentation.
When was that, JohnM? Is it something new?
Monday, September 9. The presentation and webcast audio are at https://ir.archtherapeutics.com/presentations
Have you located the unicorn yet?
$ARTH-l-ow-my current average price is $0.29. Last week, the stock appeared to open at $.20/share on high volume. Yesterday it appeared to open at $0.15/share. My offer on both days prior to open was $0.23 but, I did not fill at the lower levels which implies that these were private pre-planned transactions at $0.20 and again at $0.15. Does anyone have an idea what actually happened and whether it is bullish? bearish? neutral? for the stock going forward?
How are fills at $0.20 possibly bullish?
Capitulation?
https://ir.archtherapeutics.com/press-releases/detail/529/arch-therapeutics-provides-corporate-update-at-the-2nd
$ARTH – Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY
“On the regulatory front, as stated in the press release issued on October 2, 2019, Arch awaits acknowledgement that the notified body has completed its review process, and the next update is expected to coincide with a definitive and material announcement. No additional data has been requested by the Company’s notified body”
https://ir.archtherapeutics.com/press-releases/detail/529
ARTYH long
$ARTH Can someone help me out here? I am having trouble parsing the above statement, which is similar to one that was made about a month ago. What is throwing me are the words “next update” and “coincide”? First, “next update” – is that Arch’s next update to us or the notifying body’s update to Arch? Second, “coincide” – does this mean that Arch will have a definitive and material announcement or is it the notifying body’s update that will have a definitive and material announcement? This “coincide” part has me both worried and excited at the same time. The… Read More »
I received two news releases yesterday the first one;
https://ir.archtherapeutics.com/press-releases/detail/529
the second one;
https://ir.archtherapeutics.com/press-releases/detail/530
I read both but did not see that there was a significant difference so did not post the second think there was only an error correction. I did not print one out and compare it to the other to pinpoint the difference. It appears there has not been any change in the CE approval we are still waiting.
Why hasn’t Cleveland been back to pump this stinker?
JAM is harassing. insulting, bullying and stalking ethical as CFA and under your employment? I have ALL your posts from multiple sites. I am not a CFA.
Also have several friends at your Firm.
From the “Rock” in Glen Rock
who is JAM Cleveland and what is this all about?
I assumed he (Cleveland) is referring to Jeffery M? I have no idea what Cleveland’s post is referring to however.
sounds threatening; glad I got a screenshot! Seems to be going WWE with some random Rock reference.
Suggested solution: Don’t pump penny stocks from the 70s down to the teens and I won’t call you out
LOL at the downvotes from people who have been doubling down on the way down based upon someone pumping a penny stock. SMH
$ARTH long
https://ir.archtherapeutics.com/press-releases/detail/531/arch-therapeutics-announces-2-5-million-registered-direct
Question from a concerned investor.
I’ve invested in ARTH for three years now and hold a fair amount of shares. Should I be moving on? Is there any hope left that this company is actually going to produce stock revenues? Please!
ARTH is about to get the CE Mark for Europe. They’ve put AC5 in the hands of Key Opinion Leaders to get some case studies and start a buzz. They’ll file the IND for internal use in December or January. They are talking to multiple potential distribution partners around the world.
JohnM is on top of it. We are all waiting for the CE approval, there has been reasons given for the delay, but no facts. The only thing that can be done is to call Terry Norchi for and update. Perhaps Cleveland will stop b y if he is up to taking more abuse.
Alas, frenigon, we’re all concerned investors.
I’m hanging on to my holdings because I seem to suffer from the usual malady that as soon as I sell something, the share price goes up, and that would irritate me in the extreme after my years of holding $ARTH (since 4/30/2015).
And no., fellow $ARTH holders, I do not wish to sacrifice my shares in order to benefit the share price for the group. Sorry.
May we all yet bask on that island in the sun when we go on our victory vacation together.
Penny
We have about 37 days of fall left. Is TN going to be true to his word or not? If past performance is any indication, not. However, for the 510K approval, we did get it about when TN said we would last December. It was at that time I discussed the fact that the US Gov. closes down pretty much for the holidays and as a result they would be rushing to get all signatures needed done before the 15th. The 180 days for a 510K put it in the last week of Dec. And sure enough, the approval came… Read More »
Come on British Standards Institute, make us…well, not proud of an organization that has missed their May 28 deadline by five months, seventeen days and counting…but at least think there’s a shred of competence left.
$ARTH
CEO loves his job, travel, salary. May be after another 5 years ARTH have many more FDA approvals for different indications and no product in the market and telling investors that they are chasing approval for next big revenue stream. My ARTH dreams are dashed long ago and out.
Hope I am wrong… good luck to all ARTHs
just a thought, if I had put the same money invested in ARTH into AAPL, AMZN, MSFT, GOOG it’s worth more than double now. Hmmm…
Ah, but you didn’t . . .
$ARTH atlas long
https://ir.archtherapeutics.com/all-sec-filings/content/0001104659-19-065500/tm1919813d1_10k.htm
“We completed the biocompatibility studies required to initiate our first human trial of AC5 in Western Europe”
“Our commercialization plan for at least some of our product candidates could entail entering into one or more collaboration agreements or strategic partnerships.”
“The Company was recently notified by its Notified Body that its review team has completed its review of the Arch’s technical documentation and that it has recommended to its decision making panel that CE Marking be granted. This process is expected to be completed in early 2020.”
Great news..! They need to knuckle down and start getting busy. They shouldn’t even wait for CE confirmation and a deal – they should be working on getting the internal trials up and running. We don’t know what an external AC5 deal could bring – maybe not much. The money is in internal. So let’s get going..!
Except the rest of the 10-k wasn’t as positive. Delays in getting KOLs trials of AC5. Dilution in 2020 (while TN gives himself and others big raises). Internal development probably not making much headway until later 2020, early 2022.
No transparency or communication. OW and frustrated.
It all comes down to money. And funding. Most of the report is boiler-plate. Essentially they reserve the right to do this or that. Including raising money when they want. We know that. Let’s hope an external deal can be cut to minimize that. If not. Well they need to dilute. More. Quit putting it off. They have products that if approved will be cash-cows. Move on it now.
when do the cows come home to roost for followers of this nonsense. JMbanks , among many others have realized this is going no-where. elvis left the building years ago when avatar came on board. with his background it was obviously it was going to develop into a cash cow only for ceos etc. norchi is loving it as much as avatar. living high off the hog on dumb money,,,,,,, tax loss time is upon you, perhaps its time. if it was possible, it would hv been bought out or to market.
I don’t really buy that. At all. The original CE application got screwed up. It shouldn’t have. But human error got it submitted as a drug as opposed to a device. After that… They were on a roll. Their website had goals listed – they were knocking them down. Then – the FDA comes back on em at the 23rd hour for more info. And it is debatable whether they should have. And then all hell broke loose. Everything got massively delayed. External products started entering the market place. etc. Everyone – including Dr. Kiss – was saying the external… Read More »
dr kiss left this lock stock n barrel before he left gumshoe……
Agreed. The only reason I mentioned him was because he was the guy who brought it here. It is a start up company. High risk. High reward. We will see how it plays out.